We are fortunate to advise world-class, industry-leading companies, helping them tackle novel, complex issues and push the boundaries of technological progress. Our ability and confidence to go to trial is our core strength; our deep bench of experienced trial lawyers represents companies in their most significant matters, helping them protect their intellectual property and launch products. Our lawyers pair extensive experience in the courtroom and the boardroom with a thorough understanding of science and technology.
Intellectual Property Litigation: 'Purdue Pharma' Inequitable Conduct Invalidating Drug Patent
July 1, 2005 Full PDF
Lew Clayton's article, "'Purdue Pharma': Inequitable Conduct Invalidating Drug Patent," was featured in the July 1 edition of the New York Law Journal. The article discusses the closely watched appeal in Purdue Pharma LP v. Endo Pharmaceuticals Inc, where the Federal Circuit upheld a trial court's finding of inequitable conduct, based on the patentee's statements that misleadingly suggested there was clinical evidence supporting the efficacy of a claimed drug compound. Lew also explores recent developments in patent, trademark and copyright law, including Paul Weiss's recent victory for our client, a group of songwriters and music publishers, in Metro-Goldwyn-Mayer Studios Inc., et al. v. Grokster Ltd., one of the most significant recent copyright rulings issued by the Supreme Court. Susanna Buergel assisted in the preparation of this article.